
CLLS
Healthcare · Biotechnology · $118.9M market cap
$1.18-0.15 (-11.3%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2026 | After the close | -0.21 | 0.01 | +104.8% |
| Aug 6, 2026 | After the close | -0.25 | -0.22 | +12.0% |
| May 11, 2026 | After the close | -0.26 | -0.18 | +30.8% |
| Mar 11, 2026 | Time not confirmed | -0.29 | -0.24 | +18.6% |
| Nov 7, 2025 | After the close | -0.10 | 0.02 | +120.0% |
| Aug 4, 2025 | After the close | -0.15 | -0.22 | -46.7% |
| May 12, 2025 | After the close | -0.16 | -0.17 | -6.3% |
| Mar 14, 2025 | Time not confirmed | -0.09 | -0.16 | -77.8% |
| Nov 4, 2024 | After the close | -0.24 | -0.22 | +8.3% |
| Aug 6, 2024 | After the close | -0.27 | -0.27 | 0.0% |
| May 28, 2024 | After the close | -0.27 | -0.14 | +48.1% |
| Mar 13, 2024 | After the close | -0.22 | -0.70 | -218.2% |
| Nov 6, 2023 | After the close | -0.36 |
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients…
| -0.37 |
| -2.8% |
| Aug 3, 2023 | After the close | -0.34 | -0.15 | +55.9% |
| May 4, 2023 | After the close | -0.42 | -0.55 | -31.0% |
| Mar 8, 2023 | After the close | -0.71 | -0.59 | +16.9% |
| Nov 3, 2022 | After the close | -0.21 | -0.63 | -200.0% |
| Aug 4, 2022 | After the close | -0.57 | -0.42 | +26.3% |
| May 12, 2022 | After the close | -0.66 | -0.70 | -6.1% |
| Mar 3, 2022 | After the close | -0.92 | -0.55 | +40.2% |
| Nov 4, 2021 | After the close | -0.75 | -0.82 | -9.3% |
| Aug 5, 2021 | After the close | -0.65 | -0.88 | -35.4% |
| May 6, 2021 | After the close | -0.72 | -0.28 | +61.1% |
| Mar 4, 2021 | After the close | -0.78 | -0.95 | -21.8% |
| Nov 5, 2020 | After the close | -0.50 | -0.71 | -42.0% |
| Aug 5, 2020 | After the close | -0.74 | -0.76 | -2.7% |
| May 6, 2020 | After the close | -0.65 | 0.47 | +172.3% |
| Mar 4, 2020 | After the close | -0.73 | -0.88 | -20.5% |
| Nov 6, 2019 | After the close | -0.42 | -0.23 | +45.2% |
| Aug 6, 2019 | After the close | -0.36 | -0.65 | -80.6% |
| May 7, 2019 | After the close | -0.32 | -0.26 | +18.8% |
| Mar 11, 2019 | After the close | -0.71 | -0.53 | +25.4% |
| Nov 13, 2018 | After the close | -0.31 | -0.36 | -16.1% |
| Aug 1, 2018 | After the close | -0.34 | 0.03 | +108.8% |
| May 7, 2018 | After the close | -0.38 | -0.39 | -2.6% |
| Mar 12, 2018 | After the close | -0.72 | -0.76 | -5.6% |